Individualization of therapy using mammaprint®™: From development to the MINDACT trial

Stella Mook; Laura J. Van't Veer; Emiel J.T. Rutgers; Martine J. Piccart-Gebhart; Fatima Cardoso

Individualization of therapy using mammaprint®™: From development to the MINDACT trial

Stella Mook, Laura J. Van't Veer, Emiel J.T. Rutgers, Martine J. Piccart-Gebhart, Fatima Cardoso^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

110 Citations (Scopus)

Abstract

To date, most treatment decisions for adjuvant chemotherapy in breast cancer are based on conventional clinicopathological criteria. Since breast cancer tumors with similar clinicopathological characteristics can have strikingly different outcomes, the current selection for adjuvant chemotherapy is far from accurate. Using high-throughput microarray analysis, a 70-gene signature was identified which can accurately select early stage breast cancer patients who are highly likely to develop distant metastases, and therefore, may benefit the most from adjuvant chemotherapy. This review describes the development of the 70-gene profile (Mammaprint®™), its retrospective validation and feasibility studies, and its prospective validation in the large adjuvant MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy) clinical trial.

Original language	English
Pages (from-to)	147-156
Number of pages	10
Journal	Cancer Genomics and Proteomics
Volume	4
Issue number	3
Publication status	Published - 2007
Externally published	Yes

Keywords

70-gene profile
Breast cancer
Chemotherapy
Gene expression microarray
Mammaprint®™
MINDACT
Prognostic
Review
Validation

Cite this

@article{58bdcce5bf1e4513a379cf06dcc92e31,

title = "Individualization of therapy using mammaprint{\textregistered}{\texttrademark}: From development to the MINDACT trial",

abstract = "To date, most treatment decisions for adjuvant chemotherapy in breast cancer are based on conventional clinicopathological criteria. Since breast cancer tumors with similar clinicopathological characteristics can have strikingly different outcomes, the current selection for adjuvant chemotherapy is far from accurate. Using high-throughput microarray analysis, a 70-gene signature was identified which can accurately select early stage breast cancer patients who are highly likely to develop distant metastases, and therefore, may benefit the most from adjuvant chemotherapy. This review describes the development of the 70-gene profile (Mammaprint{\textregistered}{\texttrademark}), its retrospective validation and feasibility studies, and its prospective validation in the large adjuvant MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy) clinical trial.",

keywords = "70-gene profile, Breast cancer, Chemotherapy, Gene expression microarray, Mammaprint{\textregistered}{\texttrademark}, MINDACT, Prognostic, Review, Validation",

author = "Stella Mook and {Van't Veer}, {Laura J.} and Rutgers, {Emiel J.T.} and Piccart-Gebhart, {Martine J.} and Fatima Cardoso",

year = "2007",

language = "English",

volume = "4",

pages = "147--156",

number = "3",

}

TY - JOUR

T1 - Individualization of therapy using mammaprint®™

T2 - From development to the MINDACT trial

AU - Mook, Stella

AU - Van't Veer, Laura J.

AU - Rutgers, Emiel J.T.

AU - Piccart-Gebhart, Martine J.

AU - Cardoso, Fatima

PY - 2007

Y1 - 2007

N2 - To date, most treatment decisions for adjuvant chemotherapy in breast cancer are based on conventional clinicopathological criteria. Since breast cancer tumors with similar clinicopathological characteristics can have strikingly different outcomes, the current selection for adjuvant chemotherapy is far from accurate. Using high-throughput microarray analysis, a 70-gene signature was identified which can accurately select early stage breast cancer patients who are highly likely to develop distant metastases, and therefore, may benefit the most from adjuvant chemotherapy. This review describes the development of the 70-gene profile (Mammaprint®™), its retrospective validation and feasibility studies, and its prospective validation in the large adjuvant MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy) clinical trial.

AB - To date, most treatment decisions for adjuvant chemotherapy in breast cancer are based on conventional clinicopathological criteria. Since breast cancer tumors with similar clinicopathological characteristics can have strikingly different outcomes, the current selection for adjuvant chemotherapy is far from accurate. Using high-throughput microarray analysis, a 70-gene signature was identified which can accurately select early stage breast cancer patients who are highly likely to develop distant metastases, and therefore, may benefit the most from adjuvant chemotherapy. This review describes the development of the 70-gene profile (Mammaprint®™), its retrospective validation and feasibility studies, and its prospective validation in the large adjuvant MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy) clinical trial.

KW - 70-gene profile

KW - Breast cancer

KW - Chemotherapy

KW - Gene expression microarray

KW - Mammaprint®™

KW - MINDACT

KW - Prognostic

KW - Review

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=34249311296&partnerID=8YFLogxK

M3 - Review article

C2 - 17878518

AN - SCOPUS:34249311296

SN - 1109-6535

VL - 4

SP - 147

EP - 156

JO - Cancer Genomics and Proteomics

JF - Cancer Genomics and Proteomics

IS - 3

ER -

Individualization of therapy using mammaprint®™: From development to the MINDACT trial

Abstract

Keywords

Other files and links

Fingerprint

Cite this